Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Santhera grants Agamree rights to Nxera for DMD (PBR) +++ SANTHERA Aktie +4,56%

IPSEN Aktie

 >IPSEN Aktienkurs 
126.3 EUR    -0.9%    (Tradegate)
Ask: 127.6 EUR / 39 Stück
Bid: 127.4 EUR / 39 Stück
Tagesumsatz: 20 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
IPSEN Aktie über LYNX handeln
>IPSEN Performance
1 Woche: +6,0%
1 Monat: +3,0%
3 Monate: +8,0%
6 Monate: +24,1%
1 Jahr: +8,4%
laufendes Jahr: +6,0%
>IPSEN Aktie
Name:  IPSEN S.A. PORT. EO 1
Land:  Frankreich
Sektor:  Gesundheit
ISIN/ Wkn:  FR0010259150 / A0ESMG
Symbol/ Ticker:  I7G (Frankfurt)
Kürzel:  FRA:I7G, ETR:I7G, I7G:GR
Index:  -
Webseite:  https://www.ipsen.com/
Profil:  Ipsen S.A. is a global biopharmaceutical company s..
>Volltext..
Marktkapitalisierung:  9702.49 Mio. EUR
Unternehmenswert:  9219.4 Mio. EUR
Umsatz:  3588.23 Mio. EUR
EBITDA:  1606.14 Mio. EUR
Nettogewinn:  451.31 Mio. EUR
Gewinn je Aktie:  5.46 EUR
Schulden:  969.13 Mio. EUR
Liquide Mittel:  1456.01 Mio. EUR
Operativer Cashflow:  980.41 Mio. EUR
Bargeldquote:  1.02
Umsatzwachstum:  9.57%
Gewinnwachstum:  -34.25%
Dividende je Aktie:  1.4 EUR
Dividendenrendite:  1.2%
Dividendenschätzung:  1.2%
Div. Historie:  04.06.25 - 1.4€
30.05.24 - 1.2€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  IPSEN
Letzte Datenerhebung:  09.01.26
>IPSEN Kennzahlen
Aktien/ Unternehmen:
Aktien: 82.71 Mio. St.
Frei handelbar: 41.78%
Leerverk. Aktien: -
Rückkaufquote: 0.35%
Mitarbeiter: 5358
Umsatz/Mitarb.: 0.56 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 7.35%
Bewertung:
KGV: 22.63
KGV lG: 10.45
KUV: 2.78
KBV: 2.38
PEG-Ratio: -
EV/EBITDA: 5.74
Rentabilität:
Bruttomarge: 82.39%
Gewinnmarge: 12.58%
Operative Marge: 33.67%
Managementeffizenz:
Gesamtkaprendite: 6.7%
Eigenkaprendite: 10.82%
>IPSEN Peer Group

Es sind 68 Aktien bekannt.
 
07.01.26 - 18:33
 Ipsen - December 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire EN)
 
Monthly information relative to the total number of voting rights and shares composing the share capital...
06.01.26 - 18:03
 Ipsen – Half year statement – 2025 12 31 (GlobeNewswire EN)
 
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF...
22.12.25 - 08:36
 Ipsen Announces New Oncology Research Collaboration With Université De Montréal, IRICoR (AFX)
 
PARIS (dpa-AFX) - Ipsen S.A. (IPSEY, IPN.PA), a French biopharmaceutical company, Monday announced that it has signed a new research collaboration and option agreement with the Université de Montr......
22.12.25 - 07:03
 Ipsen expands early development pipeline with Simcere Zaiming′s innovative antibody drug conjugate (GlobeNewswire EN)
 
PARIS, FRANCE; 22 DECEMBER 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today an exclusive licensing agreement for global rights outside of Greater China, for SIM0613, an antibody-drug conjugate (ADC) with best-in-class potential. Targeting the LRRC15 protein, SIM0613 is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs....
22.12.25 - 06:55
 Simcere Pharma Licenses SIM0613 To Ipsen (AFX)
 
BEIJING (dpa-AFX) - Simcere Pharmaceutical Group Ltd. (2096.HK, SMHGF), on Monday, announced that a subsidiary, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., has entered into an exclusive lice......
22.12.25 - 06:00
 SIMCERE PHARMA Signs Exclusive Licensing Agreement with Ipsen, Eligible for Max. US$1.06B in Payments (AAStocks)
 
SIMCERE PHARMA (02096.HK)'s subsidiary Jiangsu Zaiming entered into an exclusive licensing agreement with Ipsen Pharma SAS, as announced by SIMCERE PHARMA. Ipsen would have the exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug ......
19.12.25 - 10:01
 Ipsen-Aktie fällt nach Scheitern von Phase-II-Studie zu seltener Erbkrankheit (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
19.12.25 - 07:48
 Ipsen′s Phase II FALKON Study Misses Primary Endpoint In Fibrodysplasia Ossificans Progressiva (AFX)
 
PARIS (dpa-AFX) - Ipsen (IPSEY) said on Friday that its pivotal Phase II FALKON study evaluating fidrisertib in patients with fibrodysplasia ossificans progressiva (FOP) failed to meet its primary......
19.12.25 - 07:06
 Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP) (GlobeNewswire EN)
 
PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia ossificans progressiva (FOP) vs. placebo, as a result the study will be closed. The investigational medicinal product (fidrisertib) was generally well tolerated, with no safety concerns in the trial....
15.12.25 - 17:36
 Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline (GlobeNewswire EN)
 
PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies....
08.12.25 - 18:33
 Ipsen - November 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire EN)
 
Monthly information relative to the total number of voting rights and shares composing the share capital...
05.12.25 - 07:00
 Ipsen provides update on legacy of Henri Beaufour (GlobeNewswire EN)
 
PARIS, FRANCE, 5 December 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that the shares of Beech Tree will be transferred to the Alasol Foundation, in accordance with the wishes of Mr. Henri Beaufour, Ipsen's Board Member and a representative of the founding family who passed away on November 28, 2025. This transfer is expected to take place in early 2026 after having obtained the required regulatory approvals*....
01.12.25 - 07:03
 Ipsen mourns the passing of Henri Beaufour, a founding family Board member (GlobeNewswire EN)
 
 PARIS, FRANCE, 1 DECEMBER 2025 - It is with great sadness that Ipsen (Euronext: IPN; ADR: IPSEY) today announces that Henri Beaufour, Ipsen Board Member and a representative of the founding family, passed away on Friday, 28 November 2025....
27.11.25 - 23:33
 Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline | DelveInsight (PR Newswire)
 
The rhabdomyosarcoma market is expanding as unmet needs in pediatric and young-adult populations drive increased R&D and clinical activity. Additionally, the launch of emerging therapies such as Cabozantinib (Exelixis/Ipsen), PEEL-224 (Peel Therapeutics), Orotecan (Edison Oncology),......
07.11.25 - 18:03
 Ipsen - October 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire EN)
 
Monthly information relative to the total number of voting rights and shares composing the share capital...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Eine Frau, die ein Schöngeist ist, ist die Geißel ihres Mannes, ihrer Kinder, ihrer Freunde, ihres Gesindes und der ganzen Welt. - Jean-Jacques Rousseau
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!